Twice daily cefazolin is effective for treatment of serious methicillin-sensitive Staphylococcus aureus infection in an outpatient parenteral antimicrobial therapy program.

Published in: Therapeutic advances in infectious disease (2019)

The use of twice daily cefazolin for serious MSSA infection on an OPAT program is safe and effective. Further study is needed to assess for noninferiority to conventional treatment regimes.

Keyphrases

staphylococcus aureus
quality improvement
stem cells
biofilm formation
combination therapy
methicillin resistant staphylococcus aureus
escherichia coli
cystic fibrosis
bone marrow
cell therapy